Merck to Acquire Terns Pharmaceuticals in $6.7 Billion Strategic Expansion

Merck & Co. Inc. has announced a definitive agreement to acquire Terns Pharmaceuticals in a transaction valued at approximately $6.7 billion. The deal, which has received unanimous approval from the boards of directors of both companies, represents a significant move by the pharmaceutical giant to bolster its hematology portfolio. Under the terms of the agreement, Merck will offer $53.00 per share for Terns, a figure that reflects a 31% premium over the 60-day volume-weighted average price as of March 24, 2026.

The centerpiece of this acquisition is TERN-701, an innovative treatment currently in development for chronic myeloid leukemia (CML). By integrating this asset into its existing pipeline, Merck aims to enhance its therapeutic offerings in the hematology space, demonstrating a continued commitment to advancing medical science through strategic capital investment. This move is consistent with the broader industry trend of large-cap pharmaceutical firms seeking to secure high-potential clinical assets to drive long-term growth.

From a regulatory and market perspective, the transaction underscores the ongoing vitality of the American life sciences sector. By streamlining its research and development capabilities through targeted acquisitions, Merck is positioning itself to maintain a competitive edge in a global market that increasingly rewards efficiency and innovation. Such corporate activity serves as a testament to the strength of the domestic healthcare industry, which remains a cornerstone of American economic resilience.

The closing of the acquisition is now subject to customary closing conditions, including the requirement that a majority of Terns Pharmaceuticals stockholders tender their shares in support of the deal. As the pharmaceutical sector continues to navigate complex regulatory environments, this transaction highlights the importance of fiscal responsibility and strategic foresight in corporate governance. Investors and industry analysts will be closely monitoring the tender process as the companies move toward finalizing the integration of their operations.